Virongy는 혁신적인 바이러스 연구 및 진단 기술을 개발하는 미국의 바이오기업으로,

바이러스 감염 연구와 치료법 개발을 위한 선도적인 솔루션을 제공합니다.

제품 설명 

Infectin Transduction Enhancer

제품 번호

Size 선택

제품 특징

Infectin serves as a viral and nanoparticle transduction enhancer and increases infectivity rates by 5 to 20 fold.

A cutting-edge technology in virology research

Infectin^TM is a novel adjuvant designed to facilitate viral and nanoparticle penetration of the cortical actin barrier, thereby greatly enhancing productive transduction. Infectin^TM can be used to facilitate the transduction of a variety of host cells by different viruses, viral vectors, and nanoparticles. Infectin^TM can enhance nanoparticle transduction and viral infection rates by 5 to 20-fold. Virongy developed Infectin^TM based on the scientific theory that the actin cytoskeleton is a natural barrier for viral entry and post-entry intracellular migration (Yoder et al., Cell, 2008, 134:782).

Applications

• Enhancing lenti- or retroviral transduction of target cells
• Enhancing AAV vector transduction of target cells
• Enhancing infection rates of other enveloped viruses
• Enhancing lipid nanoparticle and exosome transduction rates
• Facilitating recovery of infectious viruses from cell or tissue cultures
• Facilitating anti-viral drug screening efficiency

Important

• Once thawed, Infectin^TM should be stored at 4^oC, and is stable for 3 months.
• Do not re-freeze and do not leave Infectin^TM at room temperature.
• Infectin^TM viral infection enhancer works with most cell lines to enhance viral infection. On average, Infectin^TM enhances productive viral infection by 5- to 30-fold*.
• Infectin^TM is formulated at 10X concentration. For best results, when using Infectin^TM for the first time, start with a higher concentration (final Infectin concentration may be 2X or 3X). The lowest effective dosage can be determined through a titration experiment (final Infectin^TM concentration may be as low as 1X).
  

(*The degree of enhancement is affected by the type of virus and cells. Enhancement is strongest for enveloped viruses entering cells via membrane fusion.)

Turbo-Infectin^TM is a nano-particle enhancer that seamlessly integrates Virongy’s Infectin^TM technology with an additional attachment-enhancing buffer. This platform technology features a carefully designed large charged polymer, enhancing the binding of negatively charged nano-particles to the cell membrane surface. Our streamlined protocol has been thoughtfully optimized not only to improve transduction efficiency but also to simplify the entire process. This innovation represents a refined approach to cargo delivery, ensuring a more accessible and effective means of cellular modulation.

Turbo-Infectin^TM offers invaluable benefits for laboratory professionals and researchers engaged in cell engineering or utilizing various RNA/DNA delivery tools. By seamlessly integrating Virongy’s Infectin^TM technology with an attachment-enhancing buffer, this nano-particle enhancer streamlines the transduction process while significantly enhancing efficiency. By leveraging this dual approach, Turbo-Infectin^TM surpasses previous technologies, achieving unprecedented efficiencies in cargo delivery. Turbo-Infectin^TM empowers scientists with a versatile tool, enhancing the transduction and uptake of virus, nanoparticle, and exosome cargo, thereby accelerating breakthroughs in cellular modulation and molecular research.

Selected Publications

Selected publications from our users

Yoder, A., Yu, D., Dong, L., Iyer, S. R., Xu, X., Kelly, J., Liu, J., Wang, W., Vorster, P. J., Agulto, L., Stephany, D. A., Cooper, J. N., Marsh, J. W., & Wu, Y. (2008). HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell, 134(5), 782–792.

DeMarino, C., Cowen, M., Pleet, M.L., Pinto, D.O., Khatkar, P., Erickson, J., Docken, S.S., Russell, N., Reichmuth, B., Phan, T., et al. (2020). Differences in Transcriptional Dynamics Between T-cells and Macrophages as Determined by a Three-State Mathematical Model. Sci Rep 10, 2227.

Fu, Y., He, S., Waheed, A.A., Dabbagh, D., Zhou, Z., Trinite, B., Wang, Z., Yu, J., Wang, D., Li, F., et al. (2020). PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells. Proc Natl Acad Sci U S A.

He, S., Hetrick, B., Dabbagh, D., Akhrymuk, I.V., Kehn-Hall, K., Freed, E.O., and Wu, Y. (2020). PSGL-1 blocks SARS-CoV-2 S protein-mediated virus attachment and infection of target cells. bioRxiv.

Virongy Biosciences의 모든 제품을 만나 보세요!

Products

Virus-Specific Tools

Psedoviruses

Kits and Reagents

Transduction Enhancers

Cell Lines

Services

Viral Neutralization Assay Services

Peptide Synthesis

Vector Synthesis

Virongy Biosciences - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"